LRP6 and metastatic malignant neoplasm: In an orthotopic breast cancer mouse model in which metastatic 4T1 cells and non-metastatic 168FARN cells were injected, a treatment using the LRP6 ectodomain (LRP6N) resulted in reduction of metastasis, suggesting that LRP6 might be a suitable target for treating metastatic cancer [59].